Leaves to Take Position With Merck in Pennsylvania
CARLSBAD, Calif., Jan. 13 /PRNewswire-FirstCall/ --
The Immune Response Corporation (Nasdaq: IMNR) announced today the departure
of Dr. Ronald B. Moss, president since September of 2002, who is leaving the
Company for a position with Merck (NYSE: MRK) in Pennsylvania.
"We are saddened to see Ron leave the Company. He has put so much of his
time, talent and energy into REMUNE(R) and its therapeutic applications for
the treatment of HIV. His insights and hard work on combating the HIV/AIDS
epidemic throughout his entire career have been an inspiration to many people
here and we wish him and his family the very best in their new endeavor," said
John N. Bonfiglio PhD., chief executive officer of The Immune Response
Corporation.
Named vice president, medical and scientific affairs of The Immune
Response Corporation in January of 2000, Dr. Moss joined the Company as
medical director in 1994. He served two years as senior director of medical
and scientific affairs at the Company before being named executive director of
medical and scientific affairs in 1998.
Bonfiglio added that plans to fill the position or to consider alternatives
would be included as part of the overall strategic planning process currently
underway at the Company. He is continuing his review of Company operations
and clinical trial activities begun last week after assuming his new duties as
chief executive officer.
"We retain the core scientific and developmental proprietary know-how for
REMUNE(R) with our current professional staff and scientific advisors. We
will continue our efforts to develop REMUNE(R) as we believe it could play a
significant role in the fight against the worldwide HIV epidemic," Bonfiglio
said.
Co-founded by medical pioneer Dr. Jonas Salk and based in Carlsbad,
Calif., The Immune Response Corporation is a biopharmaceutical company
developing immune-based therapies designed to treat HIV, autoimmune diseases
and cancer. Company information is available at http://www.imnr.com .
This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, whether the Company will successfully raise
proceeds from financing activities sufficient to fund additional trials and
development of REMUNE(R), whether any such clinical trials will be successful
in meeting their primary endpoints and whether the Company will be successful
in commercializing REMUNE(R), and whether the Company will be able to continue
to successfully attract and retain key executives. These and other risk
factors are discussed more thoroughly in The Immune Response Corporation's SEC
filings, including but not limited to its report on Form 10-K for the year
ended December 31, 2001 and report on Form 10-Q for the quarter ended
September 30, 2002. The Company undertakes no obligation to publicly release
the result of any revisions to these forward-looking statements, which may be
made to reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events.
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
Company News On-Call:
http://www.prnewswire.com/comp/434675.html
CONTACT:
media, James Lee of The Lee Strategy Group,
+1-310-229-5771, or Fax, +1-310-229-5772, jlee@leestrategy.com ,
for The Immune Response Corporation; or investors, Kathy Lane of
The Immune Response Corporation, +1-760-771-2236, or Fax,
+1-760-771-2140, info@imnr.com
|
